| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 18, 2025Conduction system pacing technique may promote greater ventricular synchrony and reduce long-term risk of heart failure associated with traditional right ventricular pacing
PARIS, France, 18 September 2025 – Boston Scientific Corporation (NYSE: BSX) has received CE mark approval to expand the indication for its current-generation INGEVITY™+ Pacing Leads – thin...
-
Jul 24, 2025CE MDR approval for basivertebral nerve ablation therapy designed to provide long-lasting relief from single procedure
HEMEL HEMPSTEAD, United Kingdom, 24 July, 2025 — Boston Scientific Corporation (NYSE: BSX) today announced CE mark and first procedure in Europe with the Intracept Intraosseous Nerve Ablation...
-
Jul 10, 2025Positive guidance for the Boston Scientific FARAPULSE™ Pulsed Field Ablation System marks expansion of minimally invasive treatment options for growing number of atrial fibrillation patients in the UK.
HEMEL HEMPSTEAD, United Kingdom, 10 July 2025 – Boston Scientific Corporation (NYSE: BSX) today welcomed guidance1 supporting the use of pulsed field ablation (PFA) for the treatment of atrial...
-
Mar 3, 2025
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ --...
-
Feb 17, 2025FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with Boston Scientific mapping system to provide mapping during pulsed field ablation
LONDON, United Kingdom, 17 February, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the...
-
Jan 16, 2025
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...
Nov 16, 2024Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...
-
Nov 15, 2024
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...
-
Oct 24, 2024Diagnostic algorithm shown to detect early signs of worsening heart failure and reduce hospitalisations for patients with cardiac implantable electronic devices
HEMEL HEMPSTEAD, United Kingdom, 24 October, 2024 – Boston Scientific (NYSE: BSX) announced that the National Institute for Health and Care Excellence (NICE), which provides evidence-based...
-
Sep 9, 2024Responses of 1,000 people with chronic pain in the UK reveal the far-reaching burden of chronic pain on mental health, with many feeling misunderstood
HEMEL HEMPSTEAD, United Kingdom – 9 September, 2024 – A new survey highlights the profound impact chronic pain has on the lives of people living in the UK, often severely affecting their...